Thyroid UK has been approached again about a clinical trial investigating a new drug for Graves’ disease and wondered if you or anyone else you know might be interested in taking part. This trial was put on hold due to the COVID-19 pandemic restrictions but has now resumed recruitment, with safety considerations for hospital staff and patients.
This phase I study is investigating a potential new drug, K1-70, to treat patients who have Graves’ disease, thyroid cancer, and patients who would benefit from controlling thyroid stimulating hormone receptor (TSHR) activity.
A Safety Review Committee found the drug to have been safe and well-tolerated in the patients treated so far. A further 3 patients with Graves’ disease are needed to complete this study.
Travel to and from the study site in Manchester is provided from a patient’s chosen location, as well as accommodation for patients travelling from far, with safety measures in place.
If you would like some more information or are interested in taking part please contact the Volunteer Services team at the Medicines Evaluation Unit on 0800 655 6553 and quote “study MEU 15/304”.
They will be able to answer any questions you may have and book you in for a more in-depth discussion.
Fascinating Graves’ Antibodies Study
What is the prognosis for someone with Graves’ disease?
